FN2 Earnings Intelligence

Labcorp (LH) earnings history

Labcorp Holdings Inc. (LH) quarterly earnings scorecards, market reactions, transcript intelligence, and historical context.

Earnings History

Estimate Beat Miss Match
LH EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 3 future estimate-only quarters. Q1 '24 estimate $3.48 Q1 '24 actual $3.68, beat Q2 '24 estimate $3.78 Q2 '24 actual $3.94, beat Q3 '24 estimate $3.48 Q3 '24 actual $3.50, beat Q2 '25 estimate $4.17 Q2 '25 actual $4.35, beat Q3 '25 estimate $4.13 Q3 '25 actual $4.18, beat Q4 '25 estimate $3.95 Q4 '25 actual $4.07, beat Q1 '26 estimate $4.11 Q1 '26 actual $4.25, beat Q2 '26 estimate $4.78 Q2 '26 actual $4.99, beat Q3 '26 estimate $4.65 Q4 '26 estimate $4.40 Q1 '27 estimate $4.51
Show 1 more >
LH FY2026 Q2 · Calendar Q3 2026

Labcorp Holdings Inc.

Labcorp's Q2 supports a constructive growth case: specialty testing, consumer services and acquisitions supported profitable growth, while the raised outlook indicates management sees momentum continuing. The case remains dependent on organic volume, reimbursement and margin execution.

EPS surprise+4.4%
Market move+2.7%
LH FY2026 Q1 · Calendar Q2 2026

Labcorp Holdings Inc.

Labcorp's Q1 FY2026 reinforced the growth narrative from its full-year 2025 report. Both Diagnostics and Biopharma Laboratory Services contributed to solid enterprise revenue growth, driven by specialty and esoteric testing demand. Management raised the midpoint of full-year revenue and EPS guidance, signaling confidence that acquisitions, AI-driven efficiency gains, and specialty test expansion will offset weather-related softness and regulatory uncertainty. The company's broad partnership ecosystem and consumer health platform additions provide additional growth vectors. Policy risks around PAMA, CMS CRUSH, and ACA exchange enrollment warrant close monitoring but did not materially impair the quarter.

EPS surprise+3.4%
Market move-0.1%
LH FY2025 Q4 · Calendar Q1 2026

Labcorp Holdings Inc.

The current analysis supports a constructive but conditional view: specialty testing, partnerships, AI-enabled operations, consumer offerings, and new capacity support growth, while PAMA uncertainty, integration, early-development softness, and execution on savings remain material counterweights.

EPS surprise+3.0%
Market move-2.1%
LH FY2025 Q3 · Calendar Q4 2025

Labcorp Holdings Inc.

The current analysis supports a constructive but qualified view: Labcorp’s organic demand, specialty mix, integration work, and efficiency initiatives are supporting growth and margins. The case depends on execution against acquisitions and new tests while offsetting PAMA, Early Development, currency, and regulatory risks.

EPS surprise+1.2%
Market move-5.8%
LH FY2025 Q2 · Calendar Q3 2025

Labcorp Holdings Inc.

The supplied analysis supports a constructive operating trajectory: resilient demand, specialty-testing expansion, acquisitions, and efficiency initiatives accompanied a guidance raise. The case remains conditional on sustaining organic volume and mix, integrating acquisitions, and offsetting regulatory pressure.

EPS surprise+4.3%
Market move+6.9%

Get the LH recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.